Predictive value of cellular methods in toxicological evaluation of lead candidates: an insight to hepatotoxicity

Drug Discovery Today: Technologies

Volumn 4, Issue 3-4, 2007, Pages

  Pohjala, L ^a,b   Hakkola, J ^c   Vuorela, P ^d  

^a CDR   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c UNIVERSITY OF OULU   (Finland)

^d ÅBO AKADEMI UNIVERSITY   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; NANOMATERIAL; PARACETAMOL; POTASSIUM CHANNEL HERG;

ACUTE TOXICITY; ANTIBODY RESPONSE; CELL STRAIN HEPG2; CELL VIABILITY; CYTOTOXICITY; DRUG SCREENING; HEPATOMA CELL; HUMAN; IMMUNOGENICITY; LIVER CELL CULTURE; LIVER FAILURE; LIVER TOXICITY; NONHUMAN; REVIEW; SENSITIVITY AND SPECIFICITY; TOXICOKINETICS;

EID: 68049118361     PISSN: 17406749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddtec.2008.11.003     Document Type: Review

References (38)

1. Clemedson C., et al. MEIC evaluation of acute systemic toxicity: part VII: prediction of human toxicity by results from testing the first 30 reference chemicals with 27 further in vitro assays. ATLA 28 (2000) 161-200
2. Gülden M., et al. Impact of bioavailability on the correlation between in vitro cytotoxic and in vivo acute fish toxic concentrations of chemicals. Aquat. Toxicol. 72 (2005) 327-337
3. Pohjala L., et al. Assessing the data quality in predictive toxicology using a panel of cell lines and sytotoxicity assays. Anal. Biochem. 362 (2007) 221-228
4. Puttonen K.A., et al. Different viabilities and toxicity types after 6-OHDA and Ara-C exposure evaluated by four assays in five cell lines. Toxicol. In Vitro 22 (2008) 182-189
5. Mueller H., et al. Comparison of the usefulness of the MTT, ATP, and calcein assays to predict the potency of cytotoxic agents in various human cancer cell lines. J. Biomol. Screen 9 (2004) 506-515
6. Laaksonen T., et al. Failure of MTT as a toxicity testing agent for mesoporous silicon microparticles. Chem. Res. Toxicol. 20 (2007) 1913-1918
7. Bruggisser R., et al. Interference of plant extracts, phytoestrogens and antioxidants with MTT tetrazolium assay. Planta Med. 68 (2002) 445-448
8. Peng L., et al. Reduction of MTT by flavonoids in the absence of cells. Colloids Surf B Biointerfaces 45 (2005) 108-111
9. Vidal A., et al. Toxicological evaluation of plant extracts: Is it necessary?. In: Sharma S.K., Govil J.N., and Singh V.K. (Eds). Recent Progress in Medicinal Plants, Phytotherapeutics (2005), Studium Press LLC, USA 1-10
10. Vellonen K.S., et al. Substrates and inhibitors of efflux proteins interfere with the MTT assay in cells and may lead to underestimation of drug toxicity. Eur. J. Pharm. Sci. 23 (2004) 181-188
11. Inglese J., et al. Quantitative high-throughput screening: a titration-based approach that efficiently identifies biological activities in large chemical libraries. Proc. Natl. Acad. Sci. U.S.A. 103 (2006) 11473-11478
12. Xing J.Z., et al. Dynamic monitoring of cytotoxicity on microelectronic sensors. Chem. Res. Toxicol. 18 (2005) 154-161
13. Lee V.M. Medical progress: drug-induced hepatotoxicity. N. Engl. J. Med. 349 (2003) 474-485
14. Kaplowitz N. Idiosyncratic drug hepatotoxicity. Nat. Rev. Drug Discov. 4 (2005) 489-499
15. Navarro V.J., and Senior J.R. Drug-related hepatotoxicity. N. Engl. J. Med. 354 (2006) 731-739
16. Bessems J.G., and Vermeulen N.P. Paracetamol (acetaminophen)-induced toxicity: molecular and biochemical mechanisms, analogues and protective approaches. Crit. Rev. Toxicol. 31 (2001) 55-138
17. Lammert, C. et al. (2008) Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals. Hepatology (in press)
18. O'Brien P.J., et al. High concordance of drug-induced human hepatotoxicity with in vitro cytotoxicity measured in a novel cell-based model using high content screening. Arch. Toxicol. 80 (2006) 580-604
19. Groneberg D.A., et al. In vitro models to study hepatotoxicity. Toxicol. Pathol. 30 (2002) 394-399
20. Lerche-Langrand C., and Toutain H.J. Precision-cut liver slices: characteristics and use for in vitro pharmaco-toxicology. Toxicology 153 (2000) 221-253
21. Westerink W.M., and Schoonen W.G. Cytochrome P450 enzyme levels in HepG2 cells and cryopreserved primary human hepatocytes and their induction in HepG2 cells. Toxicol. In Vitro 21 (2007) 1581-1591
22. Westerink W.M., and Schoonen W.G. Phase II enzyme levels in HepG2 cells and cryopreserved primary human hepatocytes and their induction in HepG2 cells. Toxicol. In Vitro 21 (2007) 1592-1602
23. Dambach D.M., et al. New technologies and screening strategies for hepatotoxicity: use of in vitro models. Toxicol. Pathol. 33 (2005) 17-26
24. Guillouzo A., et al. The human hepatoma HepaRG cells: a highly differentiated model for studies of liver metabolism and toxicity of xenobiotics. Chem. Biol. Interact. 168 (2007) 66-73
25. Jose, R. et al. (2008) Long-term functional stability of human HepaRG hepatocytes and use for chronic toxicity and genotoxicity studies. Drug Metab Dispos (in press)
26. Hewitt N.J., et al. Primary hepatocytes: current understanding of the regulation of metabolic enzymes and transporter proteins, and pharmaceutical practice for the use of hepatocytes in metabolism, enzyme induction, transporter, clearance, and hepatotoxicity studies. Drug Metab. Rev. 39 (2007) 159-234
27. Xu J.J. Applications of cytotoxicity assays and pre-lethal mechanistic assays for assessment of human hepatotoxicity potential. Chem. Biol. Interact. 150 (2004) 115-128
28. Boess F., et al. Gene expression in two hepatic cell lines, cultured primary hepatocytes, and liver slices compared to the in vivo liver gene expression in rats: possible implications for toxicogenomics use of in vitro systems. Toxicol. Sci. 73 (2003) 386-402
29. Dorn A., et al. Evaluation of a high-throughput fluorescence assay method for HERG potassium channel inhibition. J. Biomol. Screen 10 (2005) 339-347
30. Murk A.J., et al. Chemical-activated luciferase gene expression (CALUX): a novel in vitro bioassay for Ah receptor active compounds in sediments and pore water. Fundam. Appl. Toxicol. 33 (1996) 149-160
31. Venhorst J., et al. Evaluation of a nocel high-throughput assay for cytochrome P450 2D6 using 7-methoxy-(4-aminomethyl)-coumarin. Eur. J. Pharm. Sci. 12 (2000) 151-158
32. Kim M.J., et al. High-throughput screening of inhibitory potential of nine cytochrome P450 enzymes in vitro using liquid chromatography/tandem mass spectrometry. Rapid Commun. Mass Spectrom. 19 (2005) 2651-2658
33. Pichler W.J. Adverse side-effects to biological agents. Allergy 61 (2006) 912-920
34. EMEA (2006) ICH Topics S 6. Preclinical safety evaluation of biotechnology-derived pharmaceuticals. http://www.emea.europa.eu/pdfs/human/ich/030295en.pdf
35. Stickler M., et al. An in vitro human cell-based assay to rank the relative immunogenicity of proteins. Toxicol. Sci. 77 (2003) 280-289
36. Koren E., et al. Clinical validation of the 'in silico' prediction of immunogenicity of a human recombinant therapeutic protein. Clin. Immunol. 124 (2007) 26-32
37. Lanone S., and Buczkowski J. Biomedical applications and potential health risks of nanomaterials: molecular mechanisms. Curr. Mol. Med. 6 (2006) 651-663
38. Xia M., et al. Compound cytotoxicity profiling using quantitative high-throughput screening. Environ. Health Perpect. 116 (2008) 284-291